Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
(NASDAQ: OLMA) Delayed: 10.00 +0.49 (5.15%)
Previous Close $9.51    52 Week High $ 
Open $9.55    52 Week Low $ 
Day High $10.02    P/E N/A 
Day Low $9.46    EPS $ 
Volume 2,548,272